Compare GRC & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRC | MESO |
|---|---|---|
| Founded | 1933 | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 1994 | 2005 |
| Metric | GRC | MESO |
|---|---|---|
| Price | $77.78 | $16.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 156.1K | ★ 176.4K |
| Earning Date | 04-23-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.04% | N/A |
| EPS Growth | ★ 32.03 | N/A |
| EPS | ★ 1.41 | N/A |
| Revenue | ★ $682,389,000.00 | N/A |
| Revenue This Year | $6.62 | $629.74 |
| Revenue Next Year | $4.66 | $30.65 |
| P/E Ratio | $55.19 | ★ N/A |
| Revenue Growth | ★ 3.44 | N/A |
| 52 Week Low | $41.85 | $12.66 |
| 52 Week High | $92.78 | $21.50 |
| Indicator | GRC | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 40.03 | 54.75 |
| Support Level | $75.97 | $15.37 |
| Resistance Level | $79.02 | $17.10 |
| Average True Range (ATR) | 2.59 | 0.37 |
| MACD | -0.51 | 0.09 |
| Stochastic Oscillator | 10.94 | 57.79 |
Gorman-Rupp Co designs, manufactures, and globally sells pumps & pump systems for use in water, wastewater, construction, dewatering, industrial, petroleum, original equipment, agriculture, fire protection, heating, ventilating & air conditioning, military, and other liquid-handling applications. It operates in one business segment, the manufacture & sale of pumps and pump systems, and generates revenue from the same. Geographically, it generates the majority of its revenue from the United States.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.